In a recent study published inStroke, an authoritative journal in the field of cardiovascular disease, researchers looked at the effects of ischemic stroke and atrial fibrillation (CMB) on the risk of major adverse cerebrovascular and cardiovascular events (MACCE) in patients with acute ischemic stroke and atrial fibrillation treated with oral anticoagulants (OAC).
also assessed whether the clinical effects of CMB vary depending on the type of OAC.
the cohort study included 1,742 patients with acute ischemic stroke accompanied by atrial fibrillation treated with OAC.
major compound outcomes are MACCE (a compound event of stroke, acute myocardial infarction, or vascular death) that occurs within 2 years based on CMB conditions.
after adjusting for a combination of factors in patients with acute ischemic stroke accompanied by atrial fibrillation taking OAC, CMB was significantly associated with the risk of future MACCE (risk ratio of 1.89 (95% CI was 1.23-2.88) ;P=0.003).
had a similar MACCE rate in 1 CMB patient compared to patients without CMB (P=0.461).
, MACCE rates were significantly higher in patients with multiple CMB (≥2), especially high-burden CMB (≥5).
MACCE occurred more frequently in patients with brain leaves and deep CMB than in patients without CMB, and there was no difference in MACCE occurrence depending on the location of CMB.
in patients treated with huafalin, CMB was significantly associated with MACCE risk (P=0.002), but not in patients treated with direct OAC (P=0.517).
results showed that in patients with acute stroke with atrial fibrillation taking OAC, the risk of future MACCE increased with the burden of CMB, and the anatomical location of CMB did not affect MACCE's risk.
the risk of taking wahfalin seems to be more pronounced.